The company remains entirely pre-revenue, with R&D expenses escalating to $5.7 million in 2026Q2 as it funds the engineering talent required for regulatory certification.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 45.44M | 46.22M | 10.51M | 6.28M | 1.06M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 26.77M | 29.56M | 6.85M | 4.75M | 919.52K |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 18.89M | 15.45M | 3.73M | 1.53M | 140.3K |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | -227.15K | 1.21M | -66K | 0 | 0 |
| Operating Income | -45.44M | -46.22M | -10.51M | -6.28M | -1.06M |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | -339.72% | -67.28% | -492.87% | - |
| EBITDA | -44.34M | -45.57M | -10.4M | -6.28M | -1.03M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | -31.99% | -337.98% | -65.57% | -508.96% | - |
| D&A (Non-Cash Add-back) | 1.1M | 650.74K | 106.92K | 0 | 0 |
| EBIT | -45.66M | -45.01M | -10.58M | -6.28M | -1.03M |
| Net Interest Income | 13.72M | 0 | 359K | 32.99K | 28K |
| Interest Income | 13.72M | 0 | 359K | 32.99K | 28K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 14.1M | 6.15M | 359K | 32.99K | 28K |
| Pretax Income | -31.34M | -40.07M | -10.15M | -6.25M | -1.03M |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -31.34M | -40.07M | -10.15M | -6.25M | -1.03M |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | 0.76% | -294.69% | -62.41% | -505.76% | - |
| Net Income (Continuing) | -31.34M | -40.07M | -10.15M | -6.25M | -1.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.61 | -1.06 | -0.39 | -0.22 | -0.04 |
| EPS Growth % | 25.13% | -171.79% | -77.27% | -509.42% | - |
| EPS (Basic) | - | -1.06 | -0.39 | -0.22 | -0.04 |
| Diluted Shares Outstanding | 51.65M | 37.91M | 26.22M | 28.57M | 28.57M |
| Basic Shares Outstanding | 51.65M | 37.91M | 26.22M | 28.57M | 28.57M |
| Dividend Payout Ratio | - | - | - | - | - |
Regulatory licensing binary outcome
As reported in recent financial filings, NNE's quarterly R&D expenditure reached $5.7 million in 2026Q2, reflecting a significant escalation from the $290.5 thousand observed in 2024Q2, as the company aggressively funds the specialized engineering and regulatory personnel required to advance its microreactor technology toward commercial viability.
The rapid expansion in operating expenses suggests that management is prioritizing technical milestones over near-term cost containment. Investors should monitor whether this spending trajectory correlates with tangible progress in NRC licensing, as the current lack of revenue makes the company entirely dependent on its existing cash reserves to sustain these elevated burn rates.
Based on the company's reported figures, NNE currently exhibits no operating leverage, as the firm has yet to generate any revenue while simultaneously increasing its quarterly operating loss to $14.1 million in 2026Q2, highlighting the heavy fixed-cost burden inherent in the pre-revenue nuclear technology development cycle.
The absence of gross profit means that every dollar of SG&A and R&D directly expands the net loss, creating a high-stakes environment for capital allocation. Until the company transitions to a commercial phase, traditional operating leverage metrics remain inapplicable, and the focus must remain on the efficiency of capital deployment relative to regulatory milestones.
According to historical income statements, NNE has utilized stock-based compensation, including a $2.1 million charge in 2026Q1, which warrants careful scrutiny as it may mask the true cash-based cost of retaining the specialized nuclear engineering talent necessary to navigate the complex NRC regulatory framework for microreactor certification.
While stock-based compensation preserves cash in the short term, it creates a persistent dilution risk for shareholders that may not be fully captured in headline net loss figures. Analysts should adjust for these non-cash charges to better understand the underlying cash burn rate and the true runway available before additional financing is required.
As indicated by the company's financial history, the lack of revenue generation combined with a quarterly net loss of $9.2 million in 2026Q2 suggests that NNE faces significant execution risk if the NRC licensing process experiences delays beyond the current multi-year development timeline projected by management.
Short-term observers might focus on the company's $203 million cash position, but this capital is highly sensitive to regulatory friction that could force extended R&D cycles. If the company fails to secure government grants or commercial partnerships, the current burn rate may necessitate further dilutive equity raises, potentially undermining the long-term value proposition for existing shareholders.
Quick answers to the most common questions about buying NNE stock.
For fiscal year 2025, Nano Nuclear Energy Inc (NNE) reported total revenue of $0.0M.
Nano Nuclear Energy Inc (NNE) reported a net loss of $40.1M for the fiscal year ending 2025.